GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan · Delayed Price · Currency is PKR

358.37

-6.27 (-1.72%)

At close: May 11, 2026

2.44% (1Y)

Market Cap	114.13B -19.4%
Revenue (ttm)	67.35B +10.1%
Net Income	10.51B +29.8%
EPS	33.00 +29.8%
Shares Out	318.47M
PE Ratio	10.86
Forward PE	9.51
Dividend	17.00 (4.66%)
Ex-Dividend Date	Apr 24, 2026

Volume	225,618
Average Volume	343,304
Open	358.90
Previous Close	364.64
Day's Range	357.50 - 363.00
52-Week Range	293.09 - 459.94
Beta	0.41
RSI	52.76
Earnings Date	Apr 27, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals

Sector Healthcare

Founded 2001

Employees 1,606

Stock Exchange Pakistan Stock Exchange

Ticker Symbol GLAXO

Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline Pakistan's revenue was 65.90 billion, an increase of 7.70% compared to the previous year's 61.19 billion. Earnings were 10.03 billion, an increase of 53.38%.

Financial Statements